![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NUDT2 |
Gene summary for NUDT2 |
![]() |
Gene information | Species | Human | Gene symbol | NUDT2 | Gene ID | 318 |
Gene name | nudix hydrolase 2 | |
Gene Alias | APAH1 | |
Cytomap | 9p13.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P50583 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
318 | NUDT2 | LZE3D | Human | Esophagus | HGIN | 4.85e-03 | 4.08e-01 | 0.0668 |
318 | NUDT2 | LZE4T | Human | Esophagus | ESCC | 1.23e-06 | 6.46e-02 | 0.0811 |
318 | NUDT2 | LZE5T | Human | Esophagus | ESCC | 3.17e-02 | 1.03e-01 | 0.0514 |
318 | NUDT2 | LZE7T | Human | Esophagus | ESCC | 1.15e-06 | 3.58e-01 | 0.0667 |
318 | NUDT2 | LZE8T | Human | Esophagus | ESCC | 1.67e-03 | -2.15e-02 | 0.067 |
318 | NUDT2 | LZE22T | Human | Esophagus | ESCC | 2.29e-04 | 2.12e-01 | 0.068 |
318 | NUDT2 | LZE24T | Human | Esophagus | ESCC | 3.74e-13 | 3.46e-01 | 0.0596 |
318 | NUDT2 | LZE6T | Human | Esophagus | ESCC | 6.23e-04 | 1.04e-01 | 0.0845 |
318 | NUDT2 | P1T-E | Human | Esophagus | ESCC | 5.05e-04 | 1.71e-01 | 0.0875 |
318 | NUDT2 | P2T-E | Human | Esophagus | ESCC | 6.12e-23 | 3.88e-01 | 0.1177 |
318 | NUDT2 | P4T-E | Human | Esophagus | ESCC | 5.78e-10 | 2.55e-01 | 0.1323 |
318 | NUDT2 | P5T-E | Human | Esophagus | ESCC | 2.16e-15 | 3.05e-01 | 0.1327 |
318 | NUDT2 | P8T-E | Human | Esophagus | ESCC | 3.84e-15 | 1.32e-01 | 0.0889 |
318 | NUDT2 | P9T-E | Human | Esophagus | ESCC | 1.41e-19 | 3.75e-01 | 0.1131 |
318 | NUDT2 | P10T-E | Human | Esophagus | ESCC | 8.45e-19 | 3.24e-01 | 0.116 |
318 | NUDT2 | P11T-E | Human | Esophagus | ESCC | 2.96e-06 | 3.85e-01 | 0.1426 |
318 | NUDT2 | P12T-E | Human | Esophagus | ESCC | 4.41e-23 | 4.01e-01 | 0.1122 |
318 | NUDT2 | P15T-E | Human | Esophagus | ESCC | 4.22e-12 | 9.11e-02 | 0.1149 |
318 | NUDT2 | P16T-E | Human | Esophagus | ESCC | 1.50e-17 | 3.05e-01 | 0.1153 |
318 | NUDT2 | P17T-E | Human | Esophagus | ESCC | 7.37e-11 | 2.92e-01 | 0.1278 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00512622 | Oral cavity | OSCC | protein tetramerization | 48/7305 | 87/18723 | 1.60e-03 | 7.62e-03 | 48 |
GO:19003631 | Oral cavity | OSCC | regulation of mRNA polyadenylation | 13/7305 | 17/18723 | 1.92e-03 | 8.94e-03 | 13 |
GO:00091272 | Oral cavity | OSCC | purine nucleoside monophosphate biosynthetic process | 15/7305 | 21/18723 | 2.65e-03 | 1.16e-02 | 15 |
GO:000914119 | Oral cavity | OSCC | nucleoside triphosphate metabolic process | 58/7305 | 112/18723 | 4.01e-03 | 1.64e-02 | 58 |
GO:20007364 | Oral cavity | OSCC | regulation of stem cell differentiation | 33/7305 | 58/18723 | 4.32e-03 | 1.75e-02 | 33 |
GO:00314421 | Oral cavity | OSCC | positive regulation of mRNA 3'-end processing | 9/7305 | 11/18723 | 4.85e-03 | 1.92e-02 | 9 |
GO:000926017 | Oral cavity | OSCC | ribonucleotide biosynthetic process | 88/7305 | 182/18723 | 6.29e-03 | 2.35e-02 | 88 |
GO:00091682 | Oral cavity | OSCC | purine ribonucleoside monophosphate biosynthetic process | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
GO:00022445 | Oral cavity | OSCC | hematopoietic progenitor cell differentiation | 57/7305 | 114/18723 | 1.09e-02 | 3.71e-02 | 57 |
GO:00488637 | Oral cavity | OSCC | stem cell differentiation | 96/7305 | 206/18723 | 1.55e-02 | 4.99e-02 | 96 |
GO:0022613110 | Oral cavity | LP | ribonucleoprotein complex biogenesis | 259/4623 | 463/18723 | 7.20e-48 | 2.25e-44 | 259 |
GO:0071826110 | Oral cavity | LP | ribonucleoprotein complex subunit organization | 130/4623 | 227/18723 | 7.54e-26 | 3.63e-23 | 130 |
GO:0022618110 | Oral cavity | LP | ribonucleoprotein complex assembly | 125/4623 | 220/18723 | 1.76e-24 | 6.91e-22 | 125 |
GO:0046034110 | Oral cavity | LP | ATP metabolic process | 128/4623 | 277/18723 | 3.95e-15 | 5.38e-13 | 128 |
GO:005068418 | Oral cavity | LP | regulation of mRNA processing | 76/4623 | 137/18723 | 1.14e-14 | 1.35e-12 | 76 |
GO:190331119 | Oral cavity | LP | regulation of mRNA metabolic process | 129/4623 | 288/18723 | 5.70e-14 | 6.10e-12 | 129 |
GO:0006979110 | Oral cavity | LP | response to oxidative stress | 181/4623 | 446/18723 | 5.74e-14 | 6.10e-12 | 181 |
GO:0062197110 | Oral cavity | LP | cellular response to chemical stress | 130/4623 | 337/18723 | 8.94e-09 | 3.52e-07 | 130 |
GO:0034599110 | Oral cavity | LP | cellular response to oxidative stress | 110/4623 | 288/18723 | 2.19e-07 | 6.65e-06 | 110 |
GO:009050111 | Oral cavity | LP | RNA phosphodiester bond hydrolysis | 63/4623 | 152/18723 | 3.88e-06 | 8.13e-05 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa002405 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa0024012 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa00240 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa002401 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0024021 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
hsa0024031 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NUDT2 | SNV | Missense_Mutation | novel | c.90N>T | p.Gln30His | p.Q30H | P50583 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
NUDT2 | SNV | Missense_Mutation | c.334N>G | p.Gln112Glu | p.Q112E | P50583 | protein_coding | deleterious(0.03) | possibly_damaging(0.468) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NUDT2 | SNV | Missense_Mutation | novel | c.439N>A | p.Ala147Thr | p.A147T | P50583 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
NUDT2 | deletion | Frame_Shift_Del | novel | c.268delA | p.Thr90GlnfsTer9 | p.T90Qfs*9 | P50583 | protein_coding | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
NUDT2 | SNV | Missense_Mutation | novel | c.439N>A | p.Ala147Thr | p.A147T | P50583 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
NUDT2 | SNV | Missense_Mutation | novel | c.151N>T | p.Asp51Tyr | p.D51Y | P50583 | protein_coding | deleterious(0.04) | possibly_damaging(0.482) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NUDT2 | SNV | Missense_Mutation | c.30C>G | p.Ile10Met | p.I10M | P50583 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-05-4389-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
NUDT2 | SNV | Missense_Mutation | c.344G>A | p.Arg115His | p.R115H | P50583 | protein_coding | deleterious(0.01) | possibly_damaging(0.825) | TCGA-49-4501-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | gemzar | PD | |
NUDT2 | SNV | Missense_Mutation | novel | c.431N>G | p.Ser144Cys | p.S144C | P50583 | protein_coding | deleterious(0) | possibly_damaging(0.645) | TCGA-90-A4EE-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
NUDT2 | SNV | Missense_Mutation | c.30C>G | p.Ile10Met | p.I10M | P50583 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-CX-7086-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |